High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up

Sarah E. Rutstein1*, Jane S. Chen2, Julie A. E. Nelson1,3, Samuel Phiri4, William C. Miller5 and Mina C. Hosseinipour1,6

Abstract
High rates of non-nucleoside reverse transcriptase inhibitors (NNRTI) resistance was a key consideration in the WHO policies transitioning first-line regimens to include integrase inhibitors (dolutegravir [DTG]). However, recent data suggests a relationship between DTG and neural tube defects among women exposed during conception, giving providers and policymakers pause regarding the planned regimen changes. We examined HIV drug resistance among a cohort of 46 acutely infected persons in Malawi. Our data demonstrates high levels of transmitted resistance, 11% using standard resistance surveillance mutations and 20% when additional NNRTI polymorphisms that may affect treatment response are included. High resistance rates in this treatment-naïve patient population reinforces the critical nature of DTG-based options in the context of public-health driven treatment programs.

Keywords: Antiretroviral resistance, Acute HIV infection, Malawi, Dolutegravir

Background
Current WHO-recommended first-line antiretroviral therapy (ART) regimens include non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz in addition to two nucleoside analogue reverse transcriptase inhibitors [1]. However, increasing prevalence of NNRTI resistance among those initiating ART have raised concerns regarding the public health implications of efavirenz-based first-line regimens [2–6], as people with NNRTI-resistance are up to three times as likely to fail first-line therapy [7–11]. In response to escalating resistance, alternative first-line regimens may be critical to preserve morbidity and mortality benefits of early ART, as well as delay or avoid costly switch to second-line ART.

Dolutegravir (DTG) has been promoted as an alternative first-line ART backbone, with potential efficacy and safety advantages over efavirenz and a very high barrier to resistance [12–14]. However, the logistical, cost, and clinical merits of such a policy shift depend directly on the underlying NNRTI-resistance patterns and prevalence. Furthermore, recent observational data from Botswana suggests a potential relationship between DTG and neural tube defects among women on DTG at time of conception has given many providers and policymakers pause regarding universal transitioning to a DTG-based backbone [15].

Here, we summarize NNRTI resistance patterns observed among treatment-naïve persons in Malawi identified with acute HIV infection (AHI). We include all mutation polymorphisms that potentially affect treatment response, as well as summarize mutations according to the WHO surveillance of drug resistance mutations list—widely accepted as those mutations most likely to represent transmitted drug resistance [16]. Our findings inform the ongoing conversation regarding risks and benefits of transitioning from efavirenz-based first-line to DTG-based first-line treatment regimens.
Analytical methods
We analyzed resistance patterns from peripheral blood specimens collected at time of enrollment among participants in a pilot study evaluating behavioral and biomedical interventions for persons with AHI in Lilongwe, Malawi. Participants were screened and enrolled into the study between June 2012 and January 2014. Description of screening and study protocols are described elsewhere (clinicaltrials.gov #NCT01450189) [17, 18]. AHI was defined as detectable HIV RNA with discordant or negative rapid HIV antibody tests. Where specimen volume allowed (39/46 specimens), repeat rapid antibody testing was conducted using rapid diagnostic assays (Determine™ HIV 1/2 Antibody [Abbott Diagnostics, Illinois US] and Uni-Gold Recombigen® HIV 1/2 [Trinity Biotech, Ireland]) to confirm antibody negative/discordancy. We did not screen for receipt of pre or post-exposure prophylaxis; PrEP was not available in Malawi at the time of the study and although remote exposure to PEP was possible, PEP exposure since the very recent infection acquisition was considered unlikely given that screening represented the first presentation to care for this cohort of acutely infected persons. Additional eligibility criteria included: above definition of AHI within 21 days of enrollment, age ≥ 18 years, and intention to remain in the Lilongwe area for the duration of study follow-up (52 weeks).

Integrase and reverse transcriptase (RT) genotypic resistance testing was performed for all participants using specimens collected at time of enrollment, which was on average 8 days after screening. All genotypic resistance testing was conducted on stored specimens after completion of study activities and thus was not available for real-time patient management. Reverse transcriptase population sequencing to determine resistance was performed as described previously [19]. After alignment using Sequencher (Gene Codes), resistance mutations were classified based on information in the Stanford University Drug Resistance Database (http://hivdb.stanford.edu/index.html). We present both the full complement of resistance mutations as well as the resistance rates as limited to those identified by the WHO surveillance of drug resistance mutations list (SDRM) [16]. Sample integrity was checked by aligning the sequences using CLC Sequence Viewer (CLC bio A/S). Ninety-five percent confidence intervals (CI) were calculated using exact methods in Stata (version 14.1, College Station, TX).

The National Health Sciences Research Committee of Malawi, the Malawi Medicines and Poisons Board, the Biomedical Institutional Review Board at University of North Carolina, Chapel Hill, and the National Institute of Allergy and Infectious Diseases’ Prevention Science Review Committee approved the procedures for this study. All study participants provided written informed consent in the local language or English, if preferred.

Results and discussion
Among 59 persons identified with AHI, 46 were enrolled into the study [20]. Of these 46 participants, 45 had resistance testing; nine (20%; 95% CI 10–35%) had at least one NNRTI resistance mutation detected (Table 1) and three had NRTI mutations detected (Table 2). There were no integrase mutations detected. Limiting likely transmitted drug resistance classification to those with mutations appearing in the SDRM list, five (11%; 95% CI 4–24%) had NNRTI resistance; the most frequent mutation was K103N, detected in four participants with any NNRTI mutations. The second most common mutation was E138A (3/9: 33%), a mutation that is not on the SDRM but which nonetheless may be clinically significant in its effect on treatment response.

### Table 1 Demographics and resistance outcomes

|                         | Total (n = 46) | No resistance (n = 36) | Any resistance (n = 9) |
|-------------------------|----------------|------------------------|------------------------|
| Age                     |                |                        |                        |
| 18–24                   | 19 (41)        | 14 (78)                | 4 (22)                 |
| 25–34                   | 20 (43)        | 15 (75)                | 5 (25)                 |
| 35–44                   | 6 (13)         | 6 (100)                | 0 (0)                  |
| ≥ 45                    | 1 (2)          | 1 (100)                | 0 (0)                  |
| Sex                     |                |                        |                        |
| Male                    | 28 (61)        | 21 (78)                | 6 (22)                 |
| Female                  | 18 (39)        | 15 (83)                | 3 (17)                 |
| Marital status          |                |                        |                        |
| Never married           | 11 (24)        |                        |                        |
| Married                 | 23 (50)        |                        |                        |
| Separated/divorced/widowed | 12 (26)      |                        |                        |
| Viral load at screening |                |                        |                        |
| ≤ 6 log_{10} copies/mL  | 24 (53)        | 19 (83)                | 4 (17)                 |
| >6 log_{10} copies/mL   | 21 (47)        | 16 (76)                | 5 (24)                 |

NNRTI resistance mutations frequencya

| Mutations | Frequency |
|-----------|-----------|
| A98G       | 2 (4.4)   |
| E138A      | 3 (6.7)   |
| K101E      | 1(2.2)    |
| K103N      | 4 (8.9)   |
| K103Q      | 1(2.2)    |
| V179E      | 1(2.2)    |
| V90I       | 1 (2.2)   |
| Y181C      | 1 (2.2)   |

aNRTI non-nucleoside reverse transcriptase inhibitors
*a Among 45 patients assessed for resistance at time of study entry
Increasing levels of ART resistance are jeopardizing the success of ART scale-up, and specifically may compromise the efficacy and effectiveness of existing first-line, efavirenz-based ART regimens. WHO surveillance demonstrates steadily increasing resistance since 2001, particularly in southern and eastern Africa [2, 6]. Pre-treatment drug resistance has previously been estimated upwards of 10% [6]; in our study, among persons with AHI, transmitted drug resistance was identified in 11% (according to SDRM definitions) and 20% of patients at least one NNRTI mutation. Observed rates are similar to those in recent WHO reports from Malawi, where 4/26 (15%) of ARV drug-naive persons had NNRTI mutations [6]. High resistance rates support the urgency of the DTG transition—a likely cost-effective programmatic shift of first-line ART regimen [21].

Vigilance is needed in monitoring response to therapy and any possible AE related to initiation of DTG. Ongoing evaluations include prospective clinical trials and observational studies focusing on several key populations (pregnant women, HIV–TB co-infection) [22]. Nonetheless, improved safety outcomes profiles, higher barriers to resistance, more favorable clinical tolerability, and cost-effectiveness modeling all suggest that DTG is a preferred first-line agent compared to efavirenz. Initiation of DTG in women of childbearing potential should be pursued cautiously, and with an informed provider and patient-population [15]. Our data demonstrates high levels of transmitted NNRTI resistance in Malawi, compromising the effectiveness EFV-based regimens. These data underscores the urgency of ongoing evaluations of the safest means by which to transition treatment initiation to DTG-based options. Persons with AHI represent a unique population for evaluation of transmitted drug resistance and similar evaluations may be warranted in other LMIC to better clarify implications of EFV-backbone as first-line therapy.

Abbreviations
AE: adverse event; AHI: acute HIV infection; ART: antiretroviral therapy; DTG: Dolutegravir; EFV: efavirenz; LMIC: low- and middle-income countries; NNRTI: non-nucleoside reverse transcriptase inhibitors; NRTI: nucleoside reverse transcriptase inhibitors; RT: reverse transcriptase; SDRM: surveillance of drug resistance mutations; WHO: World Health Organization.

Authors’ contributions
SER and MCH drafted the initial manuscript. SER, SP, WCM and MCH were all investigators on the primary clinical trial that produced this data. JSC conducted data analysis and contributed to drafting. JAEN conducted all resistance assays and analyses. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The data that support the findings of this study are available from National health Sciences Research Committee of Malawi and the Biomedical Institutional Review Board of University of North Carolina via the corresponding author; but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of above named ethic boards.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The National Health Sciences Research Committee of Malawi, the Malawi Medicines and Poisons Board, the Biomedical Institutional Review Board at University of North Carolina, Chapel Hill, and the National Institute of Allergy and Infectious Diseases’ Prevention Science Review Committee approved the procedures for this study. All study participants provided written informed consent in the local language or English, if preferred.

Funding
This work was supported by National Institutes of Health, National Institute of Allergy and Infectious Diseases [RO1 AI083059]. S.E.R. was supported by National Institutes of Health, National Institute of Mental Health [F30 MH098731]. J.S.C. was supported by National Institutes of Health, National Institute of Allergy and Infectious Diseases [T32 AI070114].

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Table 2  HIV drug resistance mutation profiles

| Profile # | NNRTI mutation | NRTI mutation |
|-----------|----------------|---------------|
| 1         | A98G, K103N    | M184V, T215F  |
| 2         | E138A          |               |
| 3         | E138A          |               |
| 4         | E138A, V179E   |               |
| 5         | K103N          |               |
| 6         | K103N          |               |
| 7         | K103N          |               |
| 8         | K103Q          |               |
| 9         | V90I, A98G, K101E, Y181C | T69N |
| 10        | None           | K219R         |

NNRTI: non-nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors, WHO: World Health Organization

* Designated mutations are not on the WHO surveillance of drug resistance mutations list and thus may be less likely to represent transmitted drug resistance.
References

1. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.

2. Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. Pre-treatment HIV drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346–55.

3. Hong SY, Jonas A, DeKlerk M, Shiningavamwe A, Desta T, Badi A, et al. Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. J Acquir Immune Defic Syndr. 2015;68(4):463–71.

4. Mungati M, Mhangara M, Gonese E, Mugurungi O, Dzangare J, Ngwende S, et al. Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008–2010. BMC Res Notes. 2016;9:302.

5. Rowley CF, MacLeod U, Maruapula D, Leikoko B, Gaseitsiwe S, Mine M, et al. Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance. J Antimicrob Chemother. 2016;71(5):1361–6.

6. World Health Organization. HIV drug resistance report 2017. Geneva: World Health Organization; 2017.

7. Avila-Rios S, García-Morales C, Matias-Florentino M, Romero-Mora KA, Tapia-Trejo D, Quiroz-Morales VS, et al. Effect of pretreatment HIV-1 drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Lancet HIV. 2016;3(12):e579–91.

8. Hammers RL, Schuurman R, Sigaloff KC, Wallis CL, Kitto C, Siwale M, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012;12(4):307–17.

9. Kanter R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, et al. Pre-treatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis. 2015;60(10):1541–9.

10. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–71.

11. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization; 2017.

12. Walmseley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuang-Josses MA, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515–9.

13. Walmseley SL, Antela A, Clumeck N, Duisculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–18.

14. Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health. 2018;6(7):e804–10.

15. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379(10):979–81.

16. Bennett DE, Camacho RL, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;4(3):e4724.

17. Rutstein SE, Pettifor AE, Phiri S, Kamanga G, Hoffman IF, Hosseinipour MC, et al. Incorporating acute HIV screening into routine HIV testing at sexually transmitted infection clinics, and HIV testing and counseling centers in Lilingwe, Malawi. J Acquir Immune Defic Syndr. 2016;71(3):272–80.

18. Rucinski KB, Rutstein SE, Powers KA, Pasquale DK, Dennis AM, Phiri S, et al. Sustained sexual behavior change following acute HIV diagnosis in Malawi. Sex Transm Dis. 2018;45:741–6.

19. Farr SL, Nelson JA, Ngombwe TJ, et al; BAN Study Team. Addition of 7 days of dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551–61.

20. Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV. 2018;5(3):e146–54.

21. Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter E, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551–61.